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Abstract
Background: HPV persistence is a key determinant of cervical carcinogenesis. The influence of postpartum on HPV
clearance has been debated. This study aimed to assess HPV clearance in later pregnancy and postpartum among
HIV-positive and negative women.
Methods: We conducted a follow-up study with 151 HPV-positive women coinfected with HIV, in 2007–2010. After
baseline assessment, all women were retested for HPV infection using PCR in later pregnancy and after delivery.
Multivariable logistic regressions assessed the putative association of covariates with HPV status in between each
one of the successive visits.
Results: Seventy-one women (47%) have eliminated HPV between the baseline visit and their second or third visits.
HIV-positive women took a significantly longer time (7.0 ± 3.8 months) to clear HPV, compared to those not infected
by HIV (5.9 ± 3.0 months). HPV clearance was significantly more likely to take place after delivery than during
pregnancy (84.5% x 15.5%).
Conclusions: Both HIV-positive and negative women presented a significant reduction in HPV infection during the
postpartum period. HIV-positive status was found to be associated with a longer period of time to clear HPV
infection in pregnant women.
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Background
Human papillomavirus (HPV) is highly prevalent in
non-vaccinated sexually active women worldwide, even
among those presenting normal cytology [1]. Most HPV
infections are transient and self-limited. Up to 90%
HPV infections are eliminated after 12–24 months [2-5].
Only 10-15% of women develop a persistent infection,
which is one of the most important risk factors for cer-
vical carcinogenesis [6-9]. Even short-time HPV persist-
ence has been associated with higher risk for cervical
intra-epithelial neoplasia, compared to women without
a history of HPV infection [10,11].
HPV clearance is more frequent in the first six months
after prime infection, with rates of 50-70% per follow-up
year [5,12,13]. Adequate cell immune response is crucial
for HPV clearance [14,15]. On the other hand, immune
tolerance/deficiency favours viral persistence and cer-
vical cancer progression [16].
HIV-positive women have a higher risk of acquiring new
HPV infections and a lower chance of clearing them com-
pared to women not infected by HIV [17-21]. Markers of
cell immunity system, e.g. higher CD4+ T cell counts, have
been associated with HPV clearance in HIV-positive
women [21,22].
Changes in immunity and other biological parameters
(e.g. changes in the levels of different hormones) during
pregnancy and postpartum may modulate the natural
history of HPV infection. Some recent studies did not
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observe differences in HPV status over time, during preg-
nancy [23-25]. Most authors, however, have found a re-
duction in HPV positivity during the postpartum period
[26-29]. Minkoff et al. [30] evaluated HIV-positive women
and documented higher numbers of new HPV types at the
postpartum period than during pregnancy, but their study
did not asses HPV clearance.
The dynamics of HPV infection during pregnancy is
not well established and information remains scarce and
controversial. Few studies have studied HPV clearance
and persistence during and after pregnancy, and just one
of them has prospectively evaluated HPV infection in
HIV-positive women. In this study, we aimed to evaluate
HPV clearance in the postpartum period of both HIV-
positive and negative women.
Methods
A prospective follow-up study was carried out between
January 2007 and January 2010, in Ribeirão Preto, São
Paulo state, Brazil. Pregnant women were selected consecu-
tively from the Prenatal Outpatient Clinic of the Infectious
Diseases Unit, Obstetrics and Gynecology Department of
the University Hospital, Medical School of Ribeirão Preto,
University of São Paulo. This is a tertiary service, which
follows-up with women previously diagnosed with HIV or
HPV infection at primary units, selected from a large
catchment population mainly composed of women from
middle and low socioeconomic strata. Women were evalu-
ated according to their HIV status and/or HPV-related le-
sion. HPV infection type was classified as clinical (in case
of warts), subclinical (in case that colposcopic lesions were
made evident), or HPV-positive (if only PCR-positive).
Inclusion criteria were as follows: 1) be in the 1st half
of pregnancy; 2) be positive for HPV, as defined by a
PCR exam; 3) be an adult (≥18 years old; so in full cap-
acity to consent or not to take part of the study accord-
ing to Brazilian law); and 4) have read and signed the
informed consent form.
Cervicovaginal samples (with 2 mL of saline solution)
were collected from all women and tested for HPV by
Polymerase Chain Reaction (PCR). Women who tested
positive for HPV were re-evaluated at two subsequent
visits: at the 2nd half of pregnancy and after delivery.
The study protocol was approved by the Ethics Review
Board of the Ribeirao Preto’s Medical School Hospital –
Sao Paulo University, and all women voluntarily signed in-
formed consent before enrolment. All patients followed
antenatal care routine of the service and no procedure was
altered for those women enrolled in the study, except for
the three PCR exams performed in each one of the visits
(during that period, PCR was not a routine exam in the
outpatient clinic).
Cervicovaginal samples were stored at −80°C until DNA
extraction, which was performed by QIAamp® DNA Mini
Kit (Qiagen, USA). Consensus primers GP5+ / GP6+ were
used to identify HPV positivity, as previously described
[31]. After that, HPV types 6 and 11, considered low-risk
HPV (LR-HPV) and 16, 18, 31 and 33, high-risk HPV
(HR-HPV), were identified simultaneously by multiplex
PCR using specific primers [32]. Every single woman had
her HPV infection typed at least once. Primers S-GH20,
pCO3 and pCO4 were used as internal controls [32,33].
Negative controls were included in every single step in
order to minimize false positive results; positive controls
used were known positive samples collected in previous
studies and belonging to a panel of positive and negative
controls.
Sample size was calculated with the help of Graphpad
StatMate® (Graphpad Software, USA). Assuming a 15%
differential clearance over time (from early pregnancy up
to postpartum), it would be necessary to include at least
99 patients, considering an 80% power and an alpha of 5%.
HPV clearance was defined as having at least one
negative result after a confirmed positive one. A negative
test detected in the 2nd visit (followed by a negative one
in the 3rd visit) was defined as “clearance”, taking place
between the 1st and the 2nd visit (i.e. clearance during
pregnancy). Women with positive tests in the first and
second visits, followed by a negative test in the 3rd visit,
were defined as “clearance” occurring between the 2nd and
the 3rd visits (i.e. clearance during the postpartum period).
Persistent infection was defined for the sake of our
study as “the consecutive detection of at least two posi-
tive HPV tests between the second and the third visit”
(considering that all women tested positive at baseline).
When a negative result appeared in between two positive
tests (i.e. between the baseline and the third visit), the
intermediate result was defined as a false negative, in
agreement with previous studies and their respective cri-
teria [34,35]. Duration of infection was estimated as the
Examined for eligibility
N=268
Excluded (51)
• Metabolic / autoimmune morbidity (N=4)
• Concurrent infection (N=1)
• HPV-negative test (N=46)
Available data for analysis (151)
• HIV-positive (N=54)
• HIV-negative (N=97)
Patients recruited
N=217
Lost to follow-up (66)
• During pregnancy (N=13)
• At postpartum period (N=53)
Figure 1 Flow diagram of study population.
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Table 1 Baseline characteristics of 151 HPV-positive women under follow-up, according to HIV status
Characteristics HIV-positive women HIV-negative women
N = 54 % N = 97 %
Marital status
Non-stable 16 29.6 35 36.1
Stable 38 70.4 62 63.9
Race/skin color
White 26 48.2 68 70.1
Brown 18 33.3 19 19.6
Black 10 18.5 10 10.3
Years of education
0-4 7 13.0 13 13.4
5-8 24 44.4 37 38.1
>9 23 42.6 47 48.4
Menarche (years)
<9 2 3.7 2 2.1
9-15 48 88.9 87 89.7
>15 4 7.4 8 8.2
Age at 1st sexual experience (years)
<16 30 55.6 63 64.9
16-20 22 40.7 31 32.0
>20 2 3.7 3 3.1
Age of 1st pregnancy (years)
<16 13 24.1 20 20.6
16-20 23 42.6 51 52.6
>20 18 33.3 26 26.8
Parity
0 11 20.4 66 68.0
1-3 38 70.4 30 30.9
≥4 5 9.2 1 1.1
Lifetime no. of sex partners
≤5 31 57.4 74 76.3
6-10 12 22.2 12 12.4
11-20 6 11.1 8 8.2
>20 5 9.3 3 3.1
Sex partners (last 12 mos.)
<3 51 94.4 92 94.8
≥3 3 5.6 5 5.2
Soking 19 35.2 18 18.6
Drug use
None 41 75.9 77 79.4
Marijuana 9 16.7 15 15.5
Cocaine/crack 4 7.4 5 5.1
Alcohol 9 16.7 11 11.3
Previous STD 37 68.5 17 17.5
Sexual partner with STD1 18 33.3 13 13.4
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period (in months) elapsed between the baseline visit
and a mid-point between the baseline visit and the first
negative result, in all cases where no positive result
followed (i.e. a false negative).
Statistical analysis was carried out with the help of
EpiInfo 3.5.3 (CDC, USA) and SAS 9.0 (SAS Institute,
USA). Paired t-tests (with Welch correction whether un-
equal variances were made evident) and chi-square test
(or Fisher Exact test for table cells with less than 5 events)
were used for univariate analysis. Multiple log-binomial
regression models were used, as the outcome was binary;
procedure PROC GENMOD was applied for model ad-
justment. Multivariable analyses were controlled for par-
ticipants’ age, smoking/non-smoking, mode of delivery,
HIV status, nature of HPV infection (clinically defined or
otherwise), and HPV type (dichotomous variable: high vs.
low risk).
Results
One hundred and fifty-one HPV-positive women were
enrolled and followed-up with, of which 54 were HIV-
positive and 97 were HIV-negative (Figure 1). Mean gesta-
tional age at entrance and at 2nd visit were 13.1 ± 4.2 and
32.6 ± 5.0 weeks, respectively. The mean visit interval did
not differ significantly among HIV-positive (5.47 ± 2.6)
and negative (5.0 ± 2.1 months) women. Mean interval be-
tween the 1st and the 2nd visit was 17.1 ± 6.3 weeks and
postpartum visit occurred 4.7 ± 2.2 months after delivery.
On average, HIV-positive women were older than HIV-
negative women (28.6 ± 6.1 years vs. 23.2 ± 6.4 years) and
had a longer follow-up period (9.6 ± 3.2 months vs. 7.8 ±
2.9 months). Most women had vaginal deliveries (53.7% of
HIV-positive and 62.0% of HIV-negative women). HIV-
positive women had a higher proportion of infections
which were exclusively detected by PCR, compared to
their HIV-negative counterparts (Table 1).
Overall genotype prevalences were as follows (in de-
scending order of frequency): 37.1% (HPV 6 / 11), 23.8%
(HPV 18), 13.2% (HPV 16), 4.0% (HPV 31), and 4.0%
(HPV 33). None of these genotypes were identified in 43
samples (28.5%). The socio-demographic characteristics,
as well as clinical and laboratory data did not signifi-
cantly differ between these women and those form
whom HPV infection was typed.
More than half of the HIV-positive women had their
condition diagnosed less than a year ago (28/54). More
than 60% of these women had CD4+ counts above 350
cells/mm3 and 44% of them present viral loads above
10,000 copies/mL.
Overall, clearance rate was 47% (71/151). The groups
among whom HPV had persisted or cleared did not differ
in median age (25.8 ± 7.5 years vs. 24.4 ± 6.0 years; p =
0.2), nor in gestational age at their 1st visit (17.3 ±
6.8 weeks vs. 17.0 ± 7.7; p = 0.87). HIV-positive and nega-
tive women did not significantly differ regarding HPV
clearance rates (48.1% vs. 46.4%; p = 0.87); but HIV-
positive women took a significantly longer time (7.0 ±
3.8 months) to clear HPV, compared to those not infected
by HIV (5.9 ± 3.0 months).
Univariate analyses are summarised in Table 2. HPV
clearance was found to be associated with the following
covariates: “to be engaged in a stable marital relationship”,
“to be white” (versus brown [biracial] and black), and “no
previous engagement in commercial sex”. “Mode of deliv-
ery”, “presentation of HPV infection” (clinical/subclinical/
HPV-positive) and “HPV type” were not found to be asso-
ciated with viral clearance. The group of women among
whom HPV has persisted showed a higher percentage of
cytological abnormalities compared to the group com-
posed by women among whom HPV was cleared (67.5%
vs. 40.8%; p = 0.002).
Clearance rate was slightly higher in women with LR-
HPV than those with HR-HPV infection, but such differ-
ence was not found to be statistically significant (20/39
(51.3%) vs. 22/56 (39.3%); p = 0.25).
Almost half of the women living with HIV infection
cleared HPV infection during follow-up (26/54). Lower
HIV viral load and higher CD4+ cell counts were found to
be associated with HPV clearance. More than 75% of HIV-
women with CD4+ count over 350 cells/mm3 cleared
HPV during follow-up (20/26) and only 4 women with less
than 1,000 copies/mL had a persistent HPV infection over
the follow-up period (4/11).
In multivariable analysis, non-smoker women had a two-
fold higher chance to clear HPV (RR 2.2; IC95% 1.1–5.0)
compared with smokers. Additional data are presented in
Table 3. The association between CD4+ cell count and
HPV clearance did not remain statistically significant after
controlling for other covariates (RR 2.0 [0.6-6.3])].
Table 1 Baseline characteristics of 151 HPV-positive women under follow-up, according to HIV status (Continued)
HPV infection type
HPV-positive 32 59.3 8 8.3
Subclinical 22 40.7 62 63.9
Clinical 0 0 27 27.8
Ribeirão Preto, 2007-2010.
1Referred by women.
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HPV clearance was made evident between the 2nd and
the 3rd (postpartum) visits in 84.5% of women who
cleared HPV infection (60/71), compared to 15.5% dur-
ing the 1st and 2nd visits (antenatal care) (11/71). Such
difference was statistically significant for women, irre-
spectively of their HIV status, as well as when analyses
were stratified by HIV status (Table 4). More than 70%
Table 2 Characteristics associated with HPV clearance
among 151 HPV-positive women (univariate analysis)
Characteristics Persistence Clearance p
N = 80 % N = 71 %
Marital status
Non-stable 34 42.5 17 23.9 <0.05*
Stable 46 57.5 54 76.1
Race/skin color
White 40 50.0 54 76.1 <0.05#
Brown 24 30.0 13 18.3
Black 16 20.0 4 5.6
Years of education
0-4 13 16.2 7 9.9 0.68#
5-8 31 38.8 30 42.2
>9 36 45.0 34 47.9
Menarche (yrs.)
<9 3 3.75 1 1.4 0.09#
9-15 74 92.5 61 85.9
>15 3 3.75 9 12.7
Age at 1st sexual experience (yrs.)
<16 54 67.5 39 54.9 0.19#
16-20 23 28.8 30 42.3
>20 3 3.7 2 2.8
Age of 1st pregnancy (yrs.)
<16 22 27.5 11 15.5 0.17*
16-20 38 47.5 36 50.7
>20 20 25.0 24 33.8
Parity
0 40 50.0 37 52.1 0.83#
1-3 38 47.5 30 42.3
≥4 2 2.5 4 5.6
Lifetime no. of sex partners
≤5 50 62.5 55 77.5 0.18#
6-10 14 17.5 10 14.1
11-20 10 12.5 4 5.6
>20 6 7.5 2 2.8
Sex partners (last 12 mos.)
<3 75 93.8 68 95.8 1.0#
≥3 5 6.2 3 4.2
HIV-positive status 28 35.0 26 36.6 0.84*
Smoking 22 27.5 15 21.1 0.36*
Drug use
None 59 73.8 59 83.1 0.39#
Marijuana 14 17.5 10 14.1
Cocaine/crack 7 8.7 2 2.8
Alcohol 15 18.8 5 7.0 0.053#
Table 2 Characteristics associated with HPV clearance
among 151 HPV-positive women (univariate analysis)
(Continued)
Previous STD 30 37.5 24 33.8 0.64*
Sexual partner with STD1 18 22.5 13 18.3 0.52*
Mode of delivery
Cesarean section 37 46.2 27 38.0 0.33
Vaginal 43 53.8 44 62.0
HPV infection type
Subclinical/clinical 60 75.0 51 71.8 0.66
HPV-positive 20 25.0 20 28.2
HPV type
High risk 34 64.1 22 54.4 0.3
Low risk 19 35.9 20 47.6
Ribeirão Preto, 2007-2010.
*Chi-square test; #Fisher Exact Test; 1Referred by women.
Table 3 Characteristics associated with HPV clearance
among 151 HPV-positive women (multivariable analysis)
Variables Adjusted RR (CI95%)*
Age (years)
>25 1
≤25 0.9 (0.5-1.5)
Smoking
Yes 1
No 2.2 (1.1-5.0)
Mode of delivery
Cesarean section
Vaginal 1.1 (0.6-1.9)
HIV status
Positive 1
Negative 1.0 (0.6-1.7)
Nature of HPV infection
Subclinical/clinical 1
HPV-positive 1.4 (0.7-2.7)
HPV type
High risk 1
Low risk 1.4 (0.9-2.3)
Ribeirão Preto, 2007-2010.
RR: Relative risk; CI95%: Confidence interval 95%.
*Adjusted for all variables listed in table.
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of HIV-negative and 90% of HIV-positive women cleared
HPV during the postpartum period.
Discussion and conclusions
Overall clearance rate in this study was 47%, which is in
agreement with previous findings, among both pregnant
[27,36] and non-pregnant women [37-39]. In a previous
Spanish study [36], pregnant women at high-risk of HPV
exposure had a clearance rate up to the post-partum
visit (53.8%) roughly comparable to our findings. Diver-
gent findings could be due to the analysis of populations
with different composition in terms of their genetic
background, nutritional and health status, as well as
longer or shorter follow-up periods. The very definition
of viral clearance has been varied in different studies.
Banura et al. [24] identified higher clearance rates in
primiparous women from Uganda than those made evi-
dent by our study, but their study differs from ours due
to the fact that the vast majority of women recruited by
them did not have any other medical conditions. An-
other difference between our studies is that the study
in Uganda computed the number of actual infections
cleared (discriminated by viral subtypes) instead of the
number of women who cleared HPV infection.
High HPV clearance rates between 68.3 and 80.7%
have been reported among non-pregnant women with-
out cytological abnormalities, under a longer follow-up
period [13,35,40,41]. On the other hand, Banura et al.
[42] documented viral clearance in 31.2% of Ugandan
non-pregnant women. The authors considered that the
low clearance rate made evident by their study was, in
part, due to new infections acquired by subjects during
the intervals between subsequent visits.
The current study identified a higher HPV clearance rate
during the postpartum period for both HIV-positive and
negative women, compared to the period covered by the
antenatal visits. These findings corroborate the results pre-
viously reported by Nobbenhuis et al. [27], who found
lower HPV positivity in women with abnormal cytology
after delivery, compared to clearance observed over all
gestational trimesters. Data eventuating from a re-analysis
of a German cohort documented a higher risk for HPV in-
fection in pregnant vis-à-vis puerperal women [28].
Cervical trauma during delivery may be associated
with lower HPV-infection rates during postpartum. Pre-
vious studies identified higher regression rates of HPV-
related lesions among women who delivered vaginally
compared to those who had Caesarean sections [43,44],
in contrast to other studies, which found similar regres-
sion rates for women who had vaginal or c-section deliv-
eries [45,46]. Ours is the first study to assess HPV
clearance in the context of different modes of delivery,
but our findings did not make evident any significant
difference between them respecting HPV clearance. (This
may be, however, due to the lack of statistical power to
fully explore such hypothesis).
More than 70% of HIV-positive women enrolled in the
study cleared HPV over time, a higher rate than has been
previously reported among non-pregnant women. Denny
et al. [47] observed an HPV clearance of 6% of South-
African non-pregnant women living with HIV, over an
18-month follow-up period. An Italian study reported a
22.8% HPV clearance rate in HIV-positive women over
14 months [19]. Our favourable evolution might therefore
be secondary to good immunologic status or relatively low
frequency of cytological abnormalities in HIV-positive
women enrolled in our study.
Brazilian health care system guarantees the full access
to free antiretroviral therapy to any eligible patient ac-
cording to criteria which are similar to the updated cri-
teria issued by the World Health Organization (WHO).
More than 90% of our patients have used this therapy
during pregnancy, which might influence our results. A
recent study has demonstrated that highly active anti-
retroviral therapy may increase the clearance of some
oncogenic HPV types [48]. These factors may have con-
founded the association between HIV status and HPV
persistence.
Ours is the first study to assess HPV clearance among
HIV-positive women during pregnancy and postpartum.
Minkoff et al. [30] compared HPV prevalence and inci-
dence in pregnancy and puerperium in HIV-positive
women. The authors identified a higher incidence rate
for HPV infection in the postpartum period.
In the HER Study (HIV Epidemiology Research),
which included more than 500 HIV-positive women,
higher CD4+ cell counts were found to be associated
with a higher HPV clearance [22]. Rowhani-Rahbar
et al. [21] identified that HPV clearance was inversely
proportional to HIV viral load and less likely to occur in
women with lower CD4+ cell count, especially among
those with CD4+ counts bellow 200 cells/mm3. A
Table 4 HPV clearance during pregnancy and postpartum period (overall and according to HIV status)
Period of
clearance
All women HIV-positive women HIV-negative women
(N = 71) (N = 26) (N = 45)
N % IC95% N % IC95% N % IC95%
Pregnancy 11 15.5 8 - 26 7 26.9 12 - 48 4 8.9 3 – 22
Postpartum period 60 84.5 74 - 92 19 73.1 52 - 88 41 91.1 78 -97
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South-African study found that low CD4+ count was
associated with a higher HPV infection incidence, but
no association with clearance was made evident by it.
Clearance was found to be exclusively associated with
HIV viral load [47]. Furthermore, it has been suggested
that HIV-HPV coinfections have a broader impact on
immunity, beyond their impact on CD4+ count [21]. In
the current study, CD4+ cell count was not found to be
associated with HPV clearance.
We further analysed the database in order to assess a
putative linear relationship between successive categor-
ies of CD4+ counts (<200, 200–350, 350–500, 500+) and
HPV clearance (data not shown). Unfortunately, we did
not observe any gradient, either because it does not exist
or because of our small sample size (beta error).
The study assessed HPV types using a modest set of
primers and HPV type-persistence was not assessed.
Further studies, profiting from a comprehensive variety
of HPV primers and a follow-up of HPV-types inci-
dence/clearance over time is sorely needed in order to
complement and validate our findings.
In longitudinal studies, clearance rates and median in-
fection duration might be underestimated due to left-
censoring of infections present at the beginning of the
study and right-censoring of infections that have not
been cleared until the end of follow-up. The current
study had a relatively short follow-up and intervals be-
tween visits, which were limited to pregnancy and post-
partum. Such a short period of time (secondary to the
logistic of the referral service) might compromise our
ability to assess HPV evaluation. Women might have
cleared their infection between visits, and it is not pos-
sible to specify the precise moment during which clear-
ance may take place. The association between HPV and
HIV coinfection might be underestimated in which case
a longer follow-up period would be necessary to prop-
erly assess it over time.
Our findings should not be generalised to other groups
of pregnant women, due to its small sample size, short
follow-up time, and the fact that our study enrolled
women from a tertiary referral care unit. Other sexually
transmitted infections were not investigated such as
Chlamydia trachomatis. Therefore, some unmeasured
confounding may have affected the adjusted risk ratios.
HPV pathophysiology is especially complex due to the
impossibility to fully differentiate persistent infections
from those which might have occurred during the interval
of two consecutive visits. Besides such caveat, a negative
HPV test may not represent the full elimination of the
virus, since latent infection may remain elusive from the
perspective of both clinical and laboratory assessments.
According to Schiffman et al. [49], HPV reappearance
after a period of latency may be common, even in the ab-
sence of immunosuppression. These controversial aspects,
combined with the transient nature HPV infection may
interfere on any assessment of the natural history of HPV
infection.
The current study aimed to better assess some contro-
versial aspects of HPV’s natural history. Postpartum period
appears to be a period of significant decline of HPV infec-
tion, among both HIV-negative and positive women. The
mode of delivery does not seem to influence this decline. A
better understanding of HPV dynamics may help to iden-
tify women at higher risk of developing HPV-related le-
sions during antenatal care, contributing to prevention of
cervical cancer, especially among HIV-positive women,
among whom such cancers tend to be especially aggressive
and harmful.
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